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Introduction 
Pheochromocytomas are tumors arising from catecholamine 
producing chromaffin cells in the adrenal medulla (1). 
They almost always produce, store, metabolize and 
secrete catecholamines. Currently the only way to cure 
pheochromocytoma is its surgical removal. Roux and 
Mayo were the first to remove pheochromocytoma in 1926 
and 1927, respectively (2). Unfortunately, due to the lack 
of understanding of pathophysiology of catecholamine 
secreting tumors and no antihypertensive medication 
adrenalectomy for pheochromocytoma was associated with 
extremely high mortality exceeding 50% (2). Only in 1956 
priestly used alpha-blockers perioperatively which resulted 
in dramatic reduction in postoperative mortality (3). In 1996 
Gagner et al. published a series of laparoscopic cases showing 
that minimally invasive access is safe and feasible (4). Over 
the last two decades adrenal gland surgery has transformed, 
so that laparoscopic access has become the gold standard 
in the surgical treatment of adrenal tumors, including 
pheochromocytomas (5,6). The advances in operative 
technique and perioperative management have lowered 
mortality rates to 0–3% with complications occurring in 
5% to 22% of patients (4,7-9). Although these numbers are 
now relatively low, perioperative hemodynamic instability 
still remains the biggest surgical and anesthetic challenge 
which apart from intraoperative bleeding is responsible for 
serious adverse events. The aim of this review was to discuss 
pre-, intra- and postoperative factors that may impact on 
hemodynamic condition of a patient.
Preoperative management
Currently the gold standard in the assessment of adrenals 
before surgery includes imaging studies (computed 
tomography, magnetic resonance, 131I-MIBG scintigraphy) 
(10,11). Additionally, hormonal activity of each tumor 
has to be evaluated. In case of pheochromocytoma urine 
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or plasma catecholamines and metanephrines levels are 
routinely used. Vanillylmandelic acid, although very 
specific for pheochromocytoma (95%) is characterized 
by rather low sensitivity (65%) (12). Both the size of 
the tumor and degree of catecholamines production 
correlates strongly with intraoperative hypertension (13). 
It is generally accepted that every patient with suspected 
pheochromocytoma requires appropriate preoperative 
optimization with antihypertensive drugs and blood volume 
expansion fluids. These precautions should be taken in 
every patient irrespective of clinical symptoms because 
undiagnosed pheochromocytoma or inadequately prepared 
patient may develop hypertensive crisis. In this situation 
mortality is close to 80% (14). In 1982 Roizen published 
a paper describing so-called Roizen criteria for adequate 
preoperative patient optimization with antihypertensive 
drugs (15). They include:
(I) No in-hospital blood pressure >160/90 mmHg for 
24 h prior to surgery;
(II) No orthostatic hypotension with blood pressure 
<80/45 mmHg;
(III) No ST or T wave changes for 1-week prior to 
surgery;
(IV) No more than f ive  premature  ventr icular 
contractions per minute.
The most commonly used drug for patients’ preparation 
is phenoxybenzamine (irreversible, noncompetitive, 
alpha-blocker) (16,17). The initial therapy is introduced 
10–14 days  pr ior  to surgery.  The init ia l  dose of 
phenoxybenzamine is 10 mg twice a day and is gradually 
increased until the clinical symptoms are controlled or side 
effects appear (usually the total daily dose is 1 mg/k/d). 
Phenoxybenzamine can be administered intravenously or 
orally and the dose is increased every 48 hours (16,18). 
There are alternative α-adrenoreceptor blockers such as: 
prazosin, terazosin and doxazosin. Although according to 
some studies they can be as effective as phenoxybenzamine, 
other studies did not support these conclusions (13,17). 
Moreover, in patients with coexisting tachyarrhythmia 
beta-blockers may be necessary. Currently, cardioselective 
beta1-blockers are preferred (metoprolol, atenolol) (18). 
In summary, appropriate preoperative alpha or/and beta-
blockade allows significant reduction in cardiovascular 
morbidity and mortality as demonstrated by Goldstein et al. 
from 69% to 3% (19). 
Although less effective, calcium channel blockers 
(amlodipine, nicardipine, nifedipine) are sometimes used 
as an alternative to alpha-blockers (16,18). However, 
they are mostly combined with the latter in patients with 
uncontrolled hypertension despite alpha-blockade or as an 
alternative in patients with severe side-effects (18). In some 
hospitals they are also used as primary preoperative agent 
in normotensive patients with pheochromocytoma (7). 
Moreover, in some institutions catecholamine synthesis 
blockers are sometimes introduced (alpha-Methyl-L-
tyrosine or metyrosine) (20-22). It significantly lowers the 
level of serum catecholamines (23). Although it has been 
shown to provide satisfactory results in blood pressure 
control preoperatively as well as intraoperatively (especially 
during induction of anesthesia or manipulation of the tumor 
when the most prominent catecholamines secretion occurs), 
its use is rather uncommon and reserved for patients with 
metastatic disease or as a combination with other alpha-
blockers (21,22,24). According to previously published 
studies such combination allows better blood pressure 
stabilization, reduced intraoperative blood loss and volume 
replacement during surgery compared to alpha-blockers 
alone (21,22). 
In tere s t ing ly,  there  a re  s tud ie s  showing  tha t 
preoperative medication seems unnecessary in case of 
pheochromocytoma. For instance, Boutros et al. basing 
on 63 cases suggested that pheochromocytoma patients 
can undergo successful surgery without preoperative 
alpha adrenergic blockade (25). Similar conclusions were 
drawn by Desmonts et al. (26). However, these results 
must be interpreted with caution. They comprise relatively 
small groups of patients with not entirely clear pre- and 
intraoperative anesthetic protocol, which does not allow 
drawing unequivocal conclusions. 
Preoperative intravenous fluid administration before 
adrenalectomy for pheochromocytoma still remains the 
major dogma. In 1954 Thompson reported improved 
outcomes after whole blood transfusions at the level greater 
than estimated intraoperative blood loss (27). However, 
the surgery for pheochromocytoma at that time was 
associated with massive blood loss due to inadequate alpha-
blockade and open approach. Later, Ulchaker reported zero 
mortality after 127 consecutive adrenalectomies in patients 
receiving intraoperatively large volumes of crystalloids and 
colloids (7). On the contrary, Gosse limited the amount 
of preoperatively administered fluids to 2,000 mL with 
satisfactory results (28). Moreover, Lebuffe et al. and 
Lentschener et al. transfused fluids intraoperatively only 
when blood pressure dropped during surgery (29,30). They 
did not report deaths related to hemodynamic instability. 
According to the most recent observations preoperative 
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intravenous fluid administration is not supported by any 
evidence-based study and does not improve outcomes in 
adrenalectomy for pheochromocytoma (17). 
Intraoperative considerations
As already mentioned surgery remains the only possible 
way to cure pheochromocytoma. The anesthetic protocol 
in this type of tumor has been previously extensively 
studied and it can be found elsewhere (16,31). There are 
several steps during surgery that are directly associated with 
sudden increase in blood pressure. They comprise changing 
the patient’s position on the operating table; induction 
of general anesthesia and intubation; intraabdominal 
pressure changes (associated with cough, light sedation, 
and insufficient relaxation or initiation of mechanical 
ventilation); creation of pneumoperitoneum or when the 
tumor is directly manipulated (32-35). According to current 
recommendations laparoscopic or retroperitoneoscopic 
approach should be preferred since it has been shown to be 
safe also in cases of pheochromocytoma (6). Like in other 
surgical disciplines minimally invasive adrenalectomy is 
associated with reduced pain, decreased blood loss, faster 
recovery and shortened length of stay (36-39). Although it is 
generally accepted that tumors smaller than 6 cm are most 
suitable for laparoscopic removal, it has been shown feasible 
also in cases of bigger lesions (40). There are several studies 
documenting the use of robotic surgery in adrenal glands 
pathology. Although it is associated with additional costs the 
intraoperative blood loss and length of stay may be reduced 
comparing classical laparoscopy (41-44). Importantly, 
pheochromocytomas may also carry a malignant potential. 
We have demonstrated that laparoscopic access can be used 
also in cases of potentially malignant pheochromocytomas 
(PASS scale >6) and is not associated with inferior long-
term outcomes (45). However, our observations suggest 
that surgery for pheochromocytoma is more difficult than 
for other adrenal tumors (46). Although the operative time 
was longer and blood loss was higher, complication rates 
remained unchanged. A study by Parnaby et al. showed 
that laparoscopic adrenalectomy for pheochromocytoma 
was indeed associated with increased episodes of severe 
intraoperative hypertension (SBP >200–220 mmHg) when 
compared to the laparoscopic resection of other adrenal 
tumors (47). Interestingly, a creation of peritoneum has 
been shown to increase catecholamines release which 
may result in hemodynamic instability (35,48,49). 
Moreover, case control studies confirmed that in terms of 
hemodynamic instability laparoscopic approach is equal to 
open procedure (50,51). Moreover, a study by Kiernan et al. 
demonstrated that after open surgery the risk of increased 
number of episodes of systolic blood pressure >200 mmHg 
was 27 times higher comparing to laparoscopy (52). 
Minimally invasive surgery requires gentle, meticulous 
dissection. Otherwise uncontrolled bleeding precludes 
good visualization of proper surgical planes. This fits 
in perfectly with the principles of pheochromocytoma 
surgery that require minimal tumor manipulation to avoid 
excessive catecholamines release. On one hand increased 
levels of catecholamines result in the increase of blood 
pressure, on the other early adrenal vein ligation decreases 
their releasing into systemic circulation leading to sudden 
hypotension. Therefore, the anesthetist must be alerted and 
fully cooperate with the surgeon. 
Postoperative management
A large number of patients require vasopressor agents in 
the early period after tumor removal. The explanation of 
this phenomenon is on one hand high concentration of 
antihypertensive drugs, relatively low volume of circulating 
blood due to chronic vasospasm caused by catecholamines 
and their sudden decrease after surgery (13,48,52,53). 
Moreover, an association between down-regulation of alpha- 
and beta-adrenergic receptors caused by catecholamines 
and postoperative hypotension was observed (54,55). The 
rate of persistent postoperative hypotension varies between 
30% and 60% and so far few studies focused on its risk 
factors (53,56-59). It has been shown that tumor size and 
preoperative levels of catecholamines (which correlate 
with tumor size) were associated with postoperative 
hemodynamic instability (53). According to Kiernan et al. 
the need for vasopressors was significantly higher after 
open procedures in univariate analysis (52). It was not 
confirmed in a multivariate model when the size of the 
tumor was additionally taken into consideration. Obviously 
open procedure is more often used in larger tumors, which 
are more hormonally active. Therefore, it is difficult to 
clearly answer the question whether it is really the type 
of surgery or the size of the tumor which in fact results 
in increased risk of hypotension after open procedure. 
On the contrary the study of Parnaby et al. comparing 
postoperative outcomes after laparoscopic adrenalectomy 
for pheochromocytoma vs. other tumors did not show any 
differences between groups (47). Although it may suggest 
that prolonged hypotension may occur irrespective of 
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hormonal status of the tumor, the study groups were small 
which does not allow explicit conclusions. In summary, 
the postoperative hypotension occurs relatively often after 
pheochromocytoma removal and may require postoperative 
use of vasopressors. It is strongly associated with tumor size 
and overproduction of catecholamines. 
Conclusions
In conclusion, hemodynamic instability is one of the most 
commonly diagnosed adverse events in patients undergoing 
laparoscopic adrenalectomy for pheochromocytoma. 
Although it occurs mostly during surgery, a significant 
proportion of patients require vasopressor agents also in 
the postoperative period. There are several risk factors 
associated with increased incidence of hemodynamic 
instability. They are directly related to the tumor size and 
its hormonal activity. Appropriate preoperative assessment 
and treatment with antihypertensive drugs significantly 
reduces the incidence of hemodynamic changes during and 
after surgery, thus minimizing serious complications and 
mortality. Moreover, operative factors seem to play crucial 
role. Meticulous dissection and gentle and minimal tumor 
manipulation and early adrenal vein ligation lower their 
incidence. Laparoscopy in the case of pheochromocytoma 
is safe and feasible. It is not associated with higher risk of 
hemodynamic instability. Such approach does not carry 
additional risk also in larger tumors. To minimize morbidity 
and mortality a close cooperation between the surgeon and 
anesthetist is mandatory in every patient with suspected or 
confirmed pheochromocytoma. 
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